Standard- vs high-dose clopidogrel after percutaneous coronary intervention

JAMA. 2011 Jun 22;305(24):2520; author reply 2521-2. doi: 10.1001/jama.2011.842.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Angioplasty, Balloon, Coronary
  • Aryl Hydrocarbon Hydroxylases / genetics
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Cardiovascular Diseases / mortality
  • Clopidogrel
  • Cytochrome P-450 CYP2C19
  • Dose-Response Relationship, Drug
  • Genetic Predisposition to Disease
  • Humans
  • Myocardial Infarction / prevention & control*
  • Platelet Activation / drug effects*
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / metabolism
  • Reproducibility of Results
  • Risk
  • Ticlopidine / administration & dosage
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / metabolism

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticlopidine